CompletedNCT06664138
Remimazolam or etomidate before electroconvulsive therapy
About this title
Read the official source — NCT06664138Medication studyAges 18–70South KoreaSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 70 years.
- Listed locations
- CheonanSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: April 28, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 30
- Sponsor
- Yeongseok Yun
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- South Korea
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT06664138
- Official title
Show the full official title
Comparison of Remimazolam and Etomidate As Induction Agents for Electroconvulsive Treatment
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cheonan
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Yeongseok Yun.
Did this study involve medication?
Yes. The study involved medication, including Remimazolam and Etomidate.
Who was this study for?
Listed age limits: 18 years to 70 years.
